Clinical features of 31 patients with Ki-1 anaplastic large-cell lymphoma.

J P Greer, Marsha C. Kinney, Robert D. Collins, +5

Journal of Clinical Oncology

Ki-1 AlclImmunologyPathologyClinical FeaturesDermatology +16

Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.

Donna Reece, Michael J. Barnett, J M Connors, +7

Journal of Clinical Oncology

ImmunologyCell Replacement TherapyPharmacotherapyMetronomic ChemotherapyImmunotherapy +18

Peripheral T-cell lymphoma: a clinicopathologic study of 42 cases.

J P Greer, Jonathan York, John B. Cousar, +4

Journal of Clinical Oncology

Hematological MalignancyLymphoid NeoplasiaMedicinePeripheral T-cell LymphomaSurgical Pathology +11

Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy.

Mary L. McMaster, J P Greer, F. Anthony Greco, +3

Journal of Clinical Oncology

Hematological MalignancyLymphoid NeoplasiaMedicineMalignant Blood DisorderImmunology +11

Non-Hodgkin's lymphoma of the gastrointestinal tract: an analysis of clinical and pathologic features affecting outcome.

Alan F. List, J P Greer, J C Cousar, +6

Journal of Clinical Oncology

Lymphoid NeoplasiaSurgical OncologyGastrointestinal OncologyMedicineHigh-grade Tumor Histology +12

Serum levels of the soluble form of CD30 molecule as a tumor marker in CD30+ anaplastic large-cell lymphoma.

Gianpaolo Nadali, Fabrizio Vinante, H. Stein, +7

Journal of Clinical Oncology

Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.

T M Waits, F. Anthony Greco, J P Greer, +5

Journal of Clinical Oncology

Large-cell lymphomas: clinical and prognostic features.

R S Stein, J P Greer, John M. Flexner, +4

Journal of Clinical Oncology

ImmunologyPathologyImmunotherapyHematological MalignancyOncology +14

Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.

Apichai Leelasiri, J P Greer, Richard S. Stein, +4

PubMed